Literature DB >> 21810450

Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study.

Allen C Cheng1, Tom Kotsimbos, Heath A Kelly, Louis B Irving, Simon D Bowler, Simon G A Brown, Mark Holmes, Christine R Jenkins, Philip Thompson, Graham Simpson, Richard Wood-Baker, Sanjaya N Senanayake, Stephen J Brady, David L Paterson, Peter A Wark, John W Upham, Tony M Korman, Dominic E Dwyer, Grant W Waterer, Paul M Kelly.   

Abstract

We aimed to estimate the effectiveness of H1N1/09 containing influenza vaccines against hospitalization from influenza in Australia. We performed a test-negative case control study in patients hospitalized in 15 sentinel Australian hospitals between March and November 2010, comparing influenza vaccination (H1N1/09 monovalent or 2010 seasonal trivalent) in hospitalized patients with PCR-confirmed influenza compared to PCR-negative controls. Between March and November 2010, 1169 hospitalized patients were tested for suspected influenza, of which influenza vaccine status was ascertained in 165/238 patients with H1N1/09 influenza, 40/64 with seasonal influenza and 558/867 test negative controls; 24% of H1N1/09 cases, 43% of seasonal influenza cases and 54% of controls were vaccinated. VE against hospitalisation with H1N1/09 influenza after adjusting for age, medical comorbidities and pregnancy status was estimated at 49% (95% CI: 13%, 70%). Influenza vaccination was associated with a reduction in hospitalisation caused by H1N1/09 influenza in the 2010 southern hemisphere winter season.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810450     DOI: 10.1016/j.vaccine.2011.07.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Epidemiology of the 2012 influenza season in Victoria, Australia.

Authors:  James Fielding; Kristina Grant; Lucinda Franklin; Sheena Sullivan; Georgina Papadakis; Heath Kelly; Allen Cheng
Journal:  Western Pac Surveill Response J       Date:  2013-08-23

2.  The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.

Authors:  Nikki Turner; Nevil Pierse; Ange Bissielo; Q Sue Huang; Michael G Baker; Marc-Alain Widdowson; Heath Kelly
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

3.  Influenza vaccine effectiveness by test-negative design - Comparison of inpatient and outpatient settings.

Authors:  Shuo Feng; Benjamin J Cowling; Sheena G Sullivan
Journal:  Vaccine       Date:  2016-02-23       Impact factor: 3.641

Review 4.  Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review.

Authors:  Sheena G Sullivan; Shuo Feng; Benjamin J Cowling
Journal:  Expert Rev Vaccines       Date:  2014-10-28       Impact factor: 5.217

5.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

Review 6.  Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies.

Authors:  Marc Rondy; Nathalie El Omeiri; Mark G Thompson; Alain Levêque; Alain Moren; Sheena G Sullivan
Journal:  J Infect       Date:  2017-09-18       Impact factor: 6.072

7.  Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND).

Authors:  Leora R Feldstein; Wesley H Self; Jill M Ferdinands; Adrienne G Randolph; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Matthew C Exline; D Clark Files; Kevin Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Natasha Halasa; Akram Khan; Christopher J Lindsell; Margaret Newhams; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay Steingrub; H Keipp Talbot; M Elizabeth Halloran; Manish Patel
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

8.  Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Emily T Martin; Caroline Cheng; Joshua G Petrie; Elif Alyanak; Manjusha Gaglani; Donald B Middleton; Shekhar Ghamande; Fernanda P Silveira; Kempapura Murthy; Richard K Zimmerman; Arnold S Monto; Christopher Trabue; H Keipp Talbot; Jill M Ferdinands
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

9.  Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine.

Authors:  Benjamin J Cowling; Vicky J Fang; Hiroshi Nishiura; Kwok-Hung Chan; Sophia Ng; Dennis K M Ip; Susan S Chiu; Gabriel M Leung; J S Malik Peiris
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

10.  Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case-control study with a rapid diagnostic test in Japan.

Authors:  Motoi Suzuki; Hiroyuki Yoshimine; Yoshitaka Harada; Naho Tsuchiya; Ikumi Shimada; Koya Ariyoshi; Kenichiro Inoue
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.